FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081383111> ?p ?o ?g. }

• W2081383111 endingPage "S52" @default.
• W2081383111 startingPage "S47" @default.
• W2081383111 abstract "Pathogenesis of myelodysplastic syndromes (MDS) involves epigenetic in addition to genetic aberrations. Gene silencing by epigenetic mechanisms is mainly mediated through variable states of DNA methylation in CpG islands within gene promoter regions in collaboration with post-translational covalent histone modifications, leading to consecutive chromatin remodelling. In patients with MDS, an increasing variety of epigenetically inactivated genes involved in cell growth, cell cycle control, differentiation, DNA repair, and cell death is known. Therefore therapeutic reversal of epigenetic silencing displays an effective treatment strategy for those patients. The use of nucleosidic DNA methyltransferase inhibitors (DNMT) 5-aza-2′ deoxycytidine (decitabine) and 5-azacytidine in different low-dose schedules has been shown to have significant activity in the treatment of MDS. Several studies demonstrated haematologic responses including CRs and PRs in up to 50% of patients, making these compounds promising treatment options especially for older patients not eligible for standard induction therapy. Recently, both drugs have been approved by the FDA for MDS treatment. In phase I/II studies using histone deacetylase (HDAC) inhibitors like sodium phenylbutyrate and valproic acid, alone or in combination with DNMTs, activity in MDS patients could also be demonstrated. In conclusion, low-dose schedules of epigenetically active drugs like DNMT and HDAC inhibitors display promising treatment options particularly for elderly MDS patients, also because of a favourable non-haematologic toxicity profile. Pathogenesis of myelodysplastic syndromes (MDS) involves epigenetic in addition to genetic aberrations. Gene silencing by epigenetic mechanisms is mainly mediated through variable states of DNA methylation in CpG islands within gene promoter regions in collaboration with post-translational covalent histone modifications, leading to consecutive chromatin remodelling. In patients with MDS, an increasing variety of epigenetically inactivated genes involved in cell growth, cell cycle control, differentiation, DNA repair, and cell death is known. Therefore therapeutic reversal of epigenetic silencing displays an effective treatment strategy for those patients. The use of nucleosidic DNA methyltransferase inhibitors (DNMT) 5-aza-2′ deoxycytidine (decitabine) and 5-azacytidine in different low-dose schedules has been shown to have significant activity in the treatment of MDS. Several studies demonstrated haematologic responses including CRs and PRs in up to 50% of patients, making these compounds promising treatment options especially for older patients not eligible for standard induction therapy. Recently, both drugs have been approved by the FDA for MDS treatment. In phase I/II studies using histone deacetylase (HDAC) inhibitors like sodium phenylbutyrate and valproic acid, alone or in combination with DNMTs, activity in MDS patients could also be demonstrated. In conclusion, low-dose schedules of epigenetically active drugs like DNMT and HDAC inhibitors display promising treatment options particularly for elderly MDS patients, also because of a favourable non-haematologic toxicity profile." @default.
• W2081383111 created "2016-06-24" @default.
• W2081383111 creator A5011540358 @default.
• W2081383111 creator A5047951694 @default.
• W2081383111 creator A5067271311 @default.
• W2081383111 date "2007-01-01" @default.
• W2081383111 modified "2023-09-26" @default.
• W2081383111 title "Targets of epigenetic therapy – Gene reactivation as a novel approach in MDS treatment" @default.
• W2081383111 cites W1484293540 @default.
• W2081383111 cites W1552528612 @default.
• W2081383111 cites W1633573136 @default.
• W2081383111 cites W1879966002 @default.
• W2081383111 cites W1966248949 @default.
• W2081383111 cites W1974840866 @default.
• W2081383111 cites W1976329147 @default.
• W2081383111 cites W1983719963 @default.
• W2081383111 cites W1996600754 @default.
• W2081383111 cites W2007042448 @default.
• W2081383111 cites W2020170592 @default.
• W2081383111 cites W2022285476 @default.
• W2081383111 cites W2022572639 @default.
• W2081383111 cites W2022733644 @default.
• W2081383111 cites W2029484950 @default.
• W2081383111 cites W2035588879 @default.
• W2081383111 cites W2050150552 @default.
• W2081383111 cites W2062145659 @default.
• W2081383111 cites W2076793651 @default.
• W2081383111 cites W2081279521 @default.
• W2081383111 cites W2091897357 @default.
• W2081383111 cites W2094375748 @default.
• W2081383111 cites W2106292925 @default.
• W2081383111 cites W2106584820 @default.
• W2081383111 cites W2109895173 @default.
• W2081383111 cites W2145337538 @default.
• W2081383111 cites W2146295849 @default.
• W2081383111 cites W2146809943 @default.
• W2081383111 cites W2163583950 @default.
• W2081383111 cites W2210620858 @default.
• W2081383111 cites W2318281771 @default.
• W2081383111 cites W2354344320 @default.
• W2081383111 cites W2501806750 @default.
• W2081383111 cites W2994542474 @default.
• W2081383111 cites W4250085880 @default.
• W2081383111 doi "https://doi.org/10.1016/j.ctrv.2007.07.009" @default.
• W2081383111 hasPublicationYear "2007" @default.
• W2081383111 type Work @default.
• W2081383111 sameAs 2081383111 @default.
• W2081383111 citedByCount "6" @default.
• W2081383111 countsByYear W20813831112013 @default.
• W2081383111 countsByYear W20813831112021 @default.
• W2081383111 crossrefType "journal-article" @default.
• W2081383111 hasAuthorship W2081383111A5011540358 @default.
• W2081383111 hasAuthorship W2081383111A5047951694 @default.
• W2081383111 hasAuthorship W2081383111A5067271311 @default.
• W2081383111 hasConcept C104317684 @default.
• W2081383111 hasConcept C114691636 @default.
• W2081383111 hasConcept C119056186 @default.
• W2081383111 hasConcept C150194340 @default.
• W2081383111 hasConcept C150425827 @default.
• W2081383111 hasConcept C190727270 @default.
• W2081383111 hasConcept C203014093 @default.
• W2081383111 hasConcept C2776239401 @default.
• W2081383111 hasConcept C2776262904 @default.
• W2081383111 hasConcept C2778305200 @default.
• W2081383111 hasConcept C2779979206 @default.
• W2081383111 hasConcept C2780007613 @default.
• W2081383111 hasConcept C2780235182 @default.
• W2081383111 hasConcept C2780737395 @default.
• W2081383111 hasConcept C2780817109 @default.
• W2081383111 hasConcept C33288867 @default.
• W2081383111 hasConcept C41091548 @default.
• W2081383111 hasConcept C50171091 @default.
• W2081383111 hasConcept C502942594 @default.
• W2081383111 hasConcept C54355233 @default.
• W2081383111 hasConcept C64927066 @default.
• W2081383111 hasConcept C71924100 @default.
• W2081383111 hasConcept C86803240 @default.
• W2081383111 hasConcept C91965660 @default.
• W2081383111 hasConceptScore W2081383111C104317684 @default.
• W2081383111 hasConceptScore W2081383111C114691636 @default.
• W2081383111 hasConceptScore W2081383111C119056186 @default.
• W2081383111 hasConceptScore W2081383111C150194340 @default.
• W2081383111 hasConceptScore W2081383111C150425827 @default.
• W2081383111 hasConceptScore W2081383111C190727270 @default.
• W2081383111 hasConceptScore W2081383111C203014093 @default.
• W2081383111 hasConceptScore W2081383111C2776239401 @default.
• W2081383111 hasConceptScore W2081383111C2776262904 @default.
• W2081383111 hasConceptScore W2081383111C2778305200 @default.
• W2081383111 hasConceptScore W2081383111C2779979206 @default.
• W2081383111 hasConceptScore W2081383111C2780007613 @default.
• W2081383111 hasConceptScore W2081383111C2780235182 @default.
• W2081383111 hasConceptScore W2081383111C2780737395 @default.
• W2081383111 hasConceptScore W2081383111C2780817109 @default.
• W2081383111 hasConceptScore W2081383111C33288867 @default.
• W2081383111 hasConceptScore W2081383111C41091548 @default.
• W2081383111 hasConceptScore W2081383111C50171091 @default.
• W2081383111 hasConceptScore W2081383111C502942594 @default.
• W2081383111 hasConceptScore W2081383111C54355233 @default.

• next